Buntanetap showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population.  Parkinson’s patients with substantial cognitive decline exhibited a very pronounced improvement. Buntanetap showed statistical improvement in the MDS-UPDRS Part II, Part III, Part II+III and Total scores in Parkinson’s patients with a >3-year diagnosis.Buntanetap showed the same statistical improvement in MDS-UPDRS Part II, Part III, Part II+III and Total scores in Parkinson’s patients with Postural Instability and Gait Difficulties (PIGD).Buntanetap’s activity resulted in statistically significant improvements in all primary and secondary endpoints in the specified populations as well as in cognition.MALVERN, Pa., July 02, 2024 (GLOBE NEWSWIRE) -- via IBN -- Annovis Bio Inc.

Buntanetap在总体登记的PD人群中显示出剂量依赖性和统计学显着的认知改善。。Buntanetap显示MDS-UPDRS第二部分，第三部分，第二部分+第三部分以及诊断>3年的帕金森病患者的总分有统计学改善。Buntanetap在MDS-UPDRS第二部分，第三部分，第二部分+第三部分以及帕金森病姿势不稳定和步态困难（PIGD）患者的总分方面显示出相同的统计学改善。Buntanetap的活动导致特定人群中所有主要和次要终点以及认知的统计学显着改善。宾夕法尼亚州马尔文，2024年7月2日（环球通讯社）——通过IBN——安诺维斯生物公司。

(NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), today announced new data from its Phase III PD study demonstrating that buntanetap is safe and effective in improving motor and non-motor activities and improving cognitive functions in patients with early Parkinson’s disease.These findings will be discussed in more detail on today's webcast at 4:30 PM ET.

（纽约证券交易所：ANVS）（“Annovis”或“公司”）是一家晚期临床药物平台公司，开创了阿尔茨海默病（AD）和帕金森病（PD）等神经退行性疾病的转化疗法，今天宣布了其III期PD研究的新数据，证明布坦塔普在改善早期帕金森病患者的运动和非运动活动以及改善认知功能方面是安全有效的。这些发现将在美国东部时间下午4:30的今天的网络广播中进行更详细的讨论。

Register here.'We are very pleased to see improvements in many of our patients over such a short course of treatment. These compelling data reinforce our commitment to advancing buntanetap into a longer study, which will allow us not only to verify observed symptomatic improvements but also to explore buntanetap’s disease-modifying properties,' said Maria Maccecchini, Ph.D., Founder, President and CEO of Annovis Bio.Key Findings from the Study:Buntanetap.

在此处注册。”我们非常高兴地看到，在如此短的疗程内，我们的许多患者都有所改善。Annovis Bio创始人、总裁兼首席执行官玛丽亚·麦克切奇尼（MariaMaccecchini）博士说，这些令人信服的数据强化了我们将布坦塔普推进更长时间研究的承诺，这将使我们不仅能够验证观察到的症状改善，而且能够探索布坦塔普的疾病缓解特性。该研究的主要发现：布坦塔普。